六味五灵片对野生型及恩替卡韦耐药HBV的抑制作用及机制
本研究旨在明确六味五灵片(LWWL)的抗HBV作用及机制。体外采用HepG2.2.15(野生型HBV)和HepG2.A64(恩替卡韦耐药HBV)细胞,体内采用流体动力学注射HBV复制小鼠模型,并结合网络药理学与转录组学分析。结果显示LWWL对两种HBV均有抑制作用,可能通过增加IFN-β和IFN-γ产生发挥作用。
要点
- LWWL(0.8 mg/ml)对野生型和恩替卡韦耐药HBV DNA、HBsAg、pgRNA均有抑制作用。
- LWWL(2 g kg-1 d-1,4周)可降低小鼠血清HBV DNA及HBsAg/HBeAg和肝组织HBsAg/HBcAg。
- 与替诺福韦相比,LWWL抑制HBV DNA较弱,但抑制抗原更有效。
核心结论
- LWWL对野生型和恩替卡韦耐药HBV均有强效抑制作用,机制可能与增加IFN-β和IFN-γ产生有关。
研究设计与样本
- 体外实验使用HepG2.2.15细胞(野生型HBV复制)和HepG2.A64细胞(恩替卡韦耐药HBV复制)。
- 体内实验使用流体动力学注射介导的HBV复制小鼠模型。
- 采用网络药理学和转录组学分析LWWL抗病毒活性成分及相关机制。
主要发现
- LWWL(0.8 mg/ml)对HepG2.2.15细胞中HBV DNA、HBsAg和pgRNA的抑制率分别为57.06%、38.55%和62.49%。
- LWWL(0.8 mg/ml)对HepG2.A64细胞中HBV DNA、HBsAg和pgRNA的抑制率分别为51.57%、17.57%和53.88%。
- LWWL(2 g kg-1 d-1,4周)治疗小鼠血清HBV DNA下降1.16 log10 IU/mL,血清HBsAg/HBeAg和肝组织HBsAg/HBcAg下降超过50%。
- 与替诺福韦对照相比,LWWL抑制HBV DNA效果较弱,但抑制HBV抗原效果更强。
临床怎么用
- LWWL可能作为抑制HBV抗原的辅助选择,尤其对恩替卡韦耐药HBV仍有体外抑制作用。
- 临床决策需结合其抑制HBV DNA作用弱于替诺福韦的特点,不能替代强效核苷(酸)类似物。
局限性
- 研究主要为体外和动物模型,缺乏临床疗效与安全性数据。
- LWWL抗HBV的具体分子机制尚未完全阐明。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Liuweiwuling Tablet (LWWL) is a licensed Chinese patent medicine (approval number: Z20060238) included in the national health insurance for anti-inflammation of chronic HBV infection, whereas its anti-HBV effect remains clarification. The study aimed to clarify its antiviral effect and related mechanisms. HepG2.2.15 cells (wild-type HBV-replicating cells) and HepG2. A64 cells (entecavir-resistant HBV-replicating cells) were used for in vitro test. Hydrodynamic injection-mediated HBV-replicating mouse model was used for in vivo test. Active compounds and related mechanisms for antiviral effect of LWWL were analyzed using network pharmacology and transcriptomics. The inhibition rates of LWWL (0.8 mg/ml) on HBV DNA, HBsAg, and pgRNA were 57.06, 38.55, and 62.49% in HepG2.2.15 cells, and 51.57, 17.57, and 53.88% in HepG2. A64 cells, respectively. LWWL (2 g kg-1 d-1 for 4 weeks)-treated mice had 1.16 log10 IU/mL decrease of serum HBV DNA, and more than 50% decrease of serum HBsAg/HBeAg and hepatic HBsAg/HBcAg. Compared to tenofovir control, LWWL was less effective in suppressing HBV DNA but more effective in suppressing HBV antigens. Thirteen differentially-expressed genes were found in relation to HBV-host interaction and some of them were enriched in interferon (IFN)-β pathway in LWWL-treated HepG2.2.15 cells. CD3+CD4+ T-cell frequency and serum IFN-γ were significantly increased in LWWL-treated mice compared to LWWL-untreated mice. Among 26 compounds with potential anti-HBV effects that were predicted by network pharmacology, four compounds (quercetin, luteolin, wogonin, and kaempferol) were experimentally confirmed to have antiviral potency. In conclusion, LWWL had potent inhibitory effect on both wild-type and entecavir-resistant HBV, which might be associated with increasing IFN-β and IFN-γ production.
引用
- Ge FL, Si LL, Yang Y, et al. Chinese Patent Medicine Liuweiwuling Tablet had Potent Inhibitory Effects on Both Wild-Type and Entecavir-Resistant Hepatitis B Virus (HBV) in vitro and Effectively Suppressed HBV Replication in Mouse Model. Front Pharmacol. 2021. PMID: 34776974. doi:10.3389/fphar.2021.756975
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。